INTRODUCTIONPast, Present and Future Drug Development for Malaria CHALLENGES AND OPPORTUNITIES IN MALARIA THERAPYScientific Challenges and Treatment Opportunities in the Face of Shifting Malaria EpidemiologyEmerging Formulation Technologies against Malaria ResurgenceTargeted Drug Delivery for Malarial TherapyThe Imminent Threat of Antimalarial Drug ResistanceCurrent Therapies and New Drug Targets for the Future Drug Development of Drug Resistant MalariaDRUG DEVELOPMENTAssays for Antimalarial Drug DiscoveryAminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology PerspectiveNatural Products as a Source for Antimalarial Drug Development Process - An OverviewMushroom-Derived Products as an Alternative Antimalarial Therapeutics: A ReviewDiscovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of AntimalarialsAntimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1, 3, 4-Oxadiazole MoietyVACCINE PERSPECTIVERecent Advances in Malaria Vaccine DevelopmentToll-Like Receptor-Based Adjuvants - A Gateway Towards Improved Malaria VaccinationPure TLR7 Agonistic BBIQ is a Potential Adjuvant against P. Berghei ANKA Challenge in Vivo
Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. The primary focus of his work is in antimalarial therapy.